Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
3794results about "Immunoglobulins against enzymes" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Super humanized antibodies
InactiveUS6881557B2Antibody mimetics/scaffoldsAnalogue computers for chemical processesHuman sequenceHumanized antibody
Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences. Top ranking human sequences are selected to provide the framework sequences for constructing a chimeric antibody that functionally replaces human CDR sequences with the non-human CDR counterparts using the selected subset member human frameworks, thereby providing a humanized antibody of high affinity and low immunogenicity without need for comparing framework sequences between the non-human and human antibodies. Chimeric antibodies made according to the method are also disclosed.
Owner:ARROWSMITH TECH
Antibody formulations
The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
Owner:GENENTECH INC
Monoclonal antibodies detection methods for enzymes that confer resistance to 2,4-dichlorophenoxyacetic acid in plants
ActiveUS8460891B2Animal cellsImmunoglobulins against cytokines/lymphokines/interferonsMonoclonal antibodyDioxygenase
Owner:CORTEVA AGRISCIENCE LLC
Monoclonal antibodies and detection methods for phosphinothricin-N-acetyl-transferase enzyme
ActiveUS9371394B2Immunoglobulins against bacteriaBiological material analysisN-acetyltransferaseAcetyltransferase
Owner:CORTEVA AGRISCIENCE LLC
Multipurpose antibody derivatives
InactiveUS6809185B1Efficient preparationEfficient productionHybrid immunoglobulinsPeptide/protein ingredientsSignalling moleculesHormones regulation
The present invention relates to a class of molecules specified as novel multipurpose antibody derivatives. This class of molecules is created by heterodimerization of two constituting components. Heterodimerization is obtained by the specific heterotypic interaction of a chosen VH-CH1 combination of immunoglobulin domains, with a chosen VL-CL combination of immunoglobulin domains. The appropriate VH and VL domains in the VHCH1 and VLCL context, a binding specificity can be constitituted by the heterodimerization scaffold itself. One or both of the comprising VHCH1 and VLCL chains can thus be extended at either the N- or the C-terminus or both with other molecules, such as a toxin polypeptide, an enzyme, a hormone, a cytokine, a signaling molecule, or a single chain linked Fv fragment with the same or a different specificity.
Owner:BIOTECNOL LTD +1
Antibodies to insulin-like growth factor I receptor
Owner:AMGEN FREMONT INC +1
Prosthetic heart valves, support structures and systems and methods for implanting same
InactiveUS20090210052A1Inhibit migrationGood tissue adhesionBalloon catheterHeart valvesProsthetic valveProsthesis
Described herein are systems and methods for operation of a prosthetic valve support structure (32) having additional reinforcement coupled with panels (36). Multiple support members (620) are distributed across the inner surface of the valve support structure (32) at regular intervals. Each support member (620) can include a looped portion (621) to act as a hinge (52). Each looped portion (621) is in a location coincidental with the interlace between adjacent panels (36).
Owner:AORTX
Detection of antigens via oligonucleotide antibody conjugates
InactiveUS6117631AHigh detection sensitivityEnhancing observed signalIn-vivo radioactive preparationsSugar derivativesDendrimerAntibody conjugate
Owner:GENISPHERE LLC
Recombinant binding proteins and peptides
DNA constructs comprise a first exon sequence of nucleotides encoding a first peptide or polypeptide, a second exon sequence of nucleotides encoding a second peptide or polypeptide and a third sequence of nucleotides between the first and second sequences encoding a heterologous intron, for example that of Tetrahymena thermophila nuclear pre-rRNA, between RNA splice sites and a site-specific recombination sequence, such as loxP, within the intron, the exons together encoding a product peptide or polypeptide. Such constructs are of use in methods of production of peptides or polypeptides, transcription leading to splicing out of the intron enabling translation of a single chain product peptide or polypeptide. Isolated nucleic acid constructs consisting essentially of a sequence of nucleotides encoding a self-splicing intron with a site-specific recombination sequence within the intron, for use in creation of constructs for expression of peptides or polypeptides, are also provided.
Owner:MEDICAL RESEARCH COUNCIL
Antagonist antibody for the treatment of cancer
ActiveUS20100047257A1High degreeStrong cytotoxicitySugar derivativesBiological material analysisSynovial sarcomaAntibody fragments
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.
Owner:SANOFI SA
Bivalent IgY antibody constructs for diagnostic and therapeutic applications
InactiveUS20070141049A1Improve the immunityIncrease contentImmunoglobulins against virusesAntibody ingredientsHeavy chainMammal
This invention relates to the field of recombinant antibody technology. It provides novel recombinant IgY antibody constructs for diagnostic and therapeutical applications. The bivalent antibody constructs display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant heavy chain domains CH2-CH4 are partly or completely of avian origin, whereas the VH, VL, CL, and CH1 domains as well as the hinge region may be of avian origin or derived from any other species. The invention allows to combine the advantages of IgY antibodies with those of established mammalian monoclonal antibodies. IgY antibody constructs comprising nonglycosylated IgY constant heavy chain domains allow to reduce unwanted interactions with C-type lectins, e.g., in human sera. Furthermore, chimeric IgY antibody containing mammalian VH, VL, CL, and CH1 domains as well as a mammalian hinge region provide a higher molecular stability than IgY antibodies in acidic conditions and, thereby, are especially suited for peroral therapeutic applications.
Owner:PLS DESIGN
Methods for treating conditions associated with MASP-2 dependent complement activation
ActiveUS20070172483A1Eliminate side effectsInhibiting complement activationCompounds screening/testingAntibody ingredientsBiological activationAlternative complement pathway
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
Owner:OMEROS CORP +1
Single-chain multiple antigen-binding molecule, its preparation and use
InactiveUS20050004352A1Reduce dissociationLess complexOrganic active ingredientsFungiAntigen bindingVariable domain
The present invention relates to a single-chain, multiple antigen-binding molecule with diverse variable domains of a heavy and of a light chain of an immunoglobulin, which are connected in the form of a VH-VL construct, which are in turn connected together via a peptide, and to the preparation and use thereof as pharmaceutical or diagnostic aid.
Owner:AFFITECH RESEARCH AS
Methods for producing highly phosphorylated lysosomal hydrolases
InactiveUS6534300B1Easy to identifyHigh mannose structureFungiBacteriaLysosomal targetingPhosphorylation
The present invention provides highly phosphorylated lysosomal hydrolases, methods of modifying lysosomal hydrolases with the lysosomal targeting pathway enzymes GlcNAc-phosphotransferase and / or phosphodiester alpha-GlcNAcase.
Owner:GENZYME CORP
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
InactiveUS20070003549A1Not effectiveExtended half-lifeNervous disorderAntipyreticVascular endothelial growth factorCancer therapy
Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.
Owner:DORMANTIS LTD
Antibodies specific for sclerostin and methods for increasing bone mineralization
ActiveUS20050106683A1Skeletal disorderImmunoglobulins against growth factorsGreek letter betaIncreased bone mineral density
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
Owner:UCB PHARMA SA
Antibody formulations
Owner:GENENTECH INC
ADAM6 mice
ActiveUS8642835B2Reduces and eliminates ADAM activityImprove fertilityHydrolasesImmunoglobulins against growth factorsMatingNucleotide sequencing
Owner:REGENERON PHARM INC
Antibodies against CD38 for treatment of multiple myeloma
ActiveUS7829673B2Compounds screening/testingSenses disorderAntiendomysial antibodiesPharmaceutical drug
Owner:GENMAB AS
Bispecific t cell activating antigen binding molecules
InactiveUS20130078249A1Increase in sizeSmall volumeAnimal cellsHybrid immunoglobulinsActivation cellsAntigen binding
The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
Owner:ROCHE GLYCART AG
Fixed dosing of HER antibodies
Owner:GENENTECH INC
Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
ActiveUS20090181855A1Peptide librariesImmunoglobulins against animals/humansPolynucleotideSynthetic antibody
The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
Owner:ADIMAB LLC
Reagents and methods for inducing an immune response to prostate specific antigen
InactiveUS6881405B2Sensitive to proteolytic degradationIncrease productionSnake antigen ingredientsAntibody ingredientsProstate-specific antigenAntibody
Owner:ONCOQUEST INC
Alaninyl maytansinol antibody conjugates
InactiveUS20120121615A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntibody conjugateMaytansinoid
Owner:GENENTECH INC
Isolated antibody which specifically binds to PCSK9
Owner:PFIZER INC RINAT NEUROSCIENCE CORP
Antibodies as T cell receptor mimics, methods of production and uses thereof
The presently disclosed and claimed invention relates to a methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies may be utilized in therapeutic methods of mediating cell lysis.
Owner:TEXAS TECH UNIV SYST
Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor
InactiveUS6989241B2High selectivityStrong specificityAnimal cellsMicrobiological testing/measurementProtein activationHybridoma cell
Owner:OKLAHOMA MEDICAL RES FOUND
Anti-ADDL antibodies and uses thereof
ActiveUS20060228349A1Prevent and treat diseaseInhibit phosphorylationNervous disorderMetabolism disorderOligomerAmyloid beta
The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β1-42.
Owner:MERCK SHARP & DOHME LLC +1
1D05 PCSK9 antagonists
ActiveUS20090246192A1Lower Level RequirementsFermentationVector-based foreign material introductionKexinSubtilisin
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
Owner:MERCK SHARP & DOHME LLC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com